Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16211327 | 0.91 | HDAC6 (0.53) | HDAC1HDAC6HDAC8HDAC5LTB4R2 | |
| SCHEMBL16211481 | 0.91 | ALDH1A1 (0.52) | HDAC1HDAC6HDAC8LMNAMAPT | |
| SCHEMBL16211284 | 0.90 | HDAC1 (0.54) | HDAC1HDAC6HDAC8LMNAHDAC5 | |
| SCHEMBL22686061 | 0.89 | HDAC1 (0.54) | HDAC1HDAC6HDAC8LMNAHDAC5 | |
| SCHEMBL16211302 | 0.89 | HDAC1 (0.66) | HDAC1HDAC6HDAC8HDAC5LTB4R2 | |
| SCHEMBL16221530 | 0.89 | HDAC6 (0.52) | HDAC1HDAC6HDAC8HDAC5LTB4R2 | |
| SCHEMBL16211616 | 0.89 | HDAC6 (0.55) | HDAC1HDAC6HDAC8LMNAHDAC5 | |
| SCHEMBL16211818 | 0.88 | HDAC1 (0.52) | HDAC1HDAC6HDAC8LMNAHDAC5 | |
| SCHEMBL16211391 | 0.88 | HDAC1 (0.50) | HDAC1HDAC6HDAC8HDAC5LTB4R2 | |
| SCHEMBL22218368 | 0.88 | HDAC1 (0.51) | HDAC1HDAC6HDAC8LMNAHDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571426-B2 | Compositions for preventing or treating lupus | CHONG KUN DANG PHARMACEUTICAL CORP. | 2023-02-07 | — | — | US | disclosed |
| US-11571426-B2 | Compositions for preventing or treating lupus | CHONG KUN DANG PHARMACEUTICAL CORP. | 2023-02-07 | — | — | US | disclosed |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-03-18 | — | — | US | disclosed |
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-03-18 | — | — | US | disclosed |
| EP-3755336-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | Chong Kun Dang Pharmaceutical Corp. (KR) | 2020-12-30 | — | — | EP | disclosed |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-11-26 | — | — | US | disclosed |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-11-26 | — | — | US | disclosed |
| CN-111801101-A | Composition for preventing or treating uveitis | 株式会社钟根堂 | 2020-10-20 | — | — | CN | disclosed |
| EP-3713578-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | Chong Kun Dang Pharmaceutical Corp. (KR) | 2020-09-30 | — | — | EP | disclosed |
| CN-111372589-A | Composition for preventing or treating lupus | 株式会社钟根堂 | 2020-07-03 | — | — | CN | disclosed |
| WO-2019103524-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-31 | — | — | WO | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-9878986-B2 | Compounds for selective histone deacetylase inhibitors, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2018-01-30 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2991982-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-03-09 | — | — | EP | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014178606-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077501-A1 | COMPOSITIONS FOR PREVENTING OR TREATING UVEITIS | UACA, PDE6C, PDE6H | HDAC1 344/4885HDAC6 122/4885HDAC8 716/4885 |
| US-11571426-B2 | Compositions for preventing or treating lupus | SSB, TLR9, TLR5 | HDAC1 96/4885HDAC6 203/4885HDAC8 444/4885 |
| US-20160083354-A1 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | HDAC1 1/4885HDAC6 5/4885HDAC8 10/4885 |
| US-20170152230-A9 | NOVEL COMPOUNDS FOR SELECTIVE HISTONE DEACETYLASE INHIBITORS, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC1, HDAC5, HDAC4 | HDAC1 1/4885HDAC6 5/4885HDAC8 10/4885 |
| US-20200368245-A1 | COMPOSITIONS FOR PREVENTING OR TREATING LUPUS | SSB, TLR9, TLR5 | HDAC1 96/4885HDAC6 203/4885HDAC8 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.